A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS619-TPS619, 1p
- Subject
- Language
- ISSN
- 0732183X